A natural molecule boosts CAR-T therapy and turns cold tumors hot
April 29, 2026
A pharmaceutical research team has identified a natural compound, timosaponin AIII (TAIII), that selectively eliminates CAR-T regulatory T cells.
A pharmaceutical research team has identified a natural compound, timosaponin AIII (TAIII), that selectively eliminates CAR-T regulatory T cells.
Researchers at Karolinska Institutet, in collaboration with colleagues at The Scripps Research Institute and Emory University, have developed a new vaccine strategy that has generated antibodies capable of neutralizing highly divergent HIV variants.
Medtronic (NYSE:MDT) announced today that it received FDA approval for its Mosaic Neo mitral bioprosthesis and began its U.S. launch.
Earflo announced that it received FDA clearance for its non-invasive device designed to treat negative middle ear pressure in children.
In a study published in the New England Journal of Medicine, researchers at UC San Francisco and UC Irvine show the device is as effective as a laboratory test and can detect cases even among people who have trouble producing phlegm samples from deep within their lungs.
Researchers at Johns Hopkins Medicine say they have successfully demonstrated that disrupting an eye structure long suspected of blocking the growth and survival of transplanted nerve cells may help restore vision in people with optic nerve damage.
Researchers developed the Cardiac Autoregressive Model for ECG Language-Modeling (CAMEL), an artificial intelligence model that treats ECG less like isolated snapshots and more like language.
Researchers developed a “tumor-on-a-chip” system designed to recreate that environment outside the human body, offering a more realistic way to study the disease and evaluate treatments.
Professor Iksung Kang (School of Electrical Engineering), in collaboration with Professor Na Ji’s research team at UC Berkeley, has developed a technology that accurately corrects image aberrations in microscopes used for live biological imaging.
LAGUNA HILLS, Calif., April 29, 2026 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in precision diagnostics for early-stage breast cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the AidaBREAST® test.